Recent Updates
Recently added Catalysts
RGEN Neutral Sentiment

Repligen to Report First Quarter 2026 Financial Results

Key Takeaway: Repligen Corporation will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The company plans to issue a press release before the market opens that day. A conference call will follow at 8:00 a.m. ET to discuss business updates. This call covers the three-month period ended March 31, 2026.
Price reaction · baseline $132.7 (2026-04-21 close) · hit after-hours · clean, no other RGEN news in the window
day 0 close
-6.3%
day 1 · peak
-14%
day 3
-10.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Repligen Corporation will report its financial results soon, indicating potential growth.
  • The conference call provides an opportunity for transparency and investor engagement.

Full Press Release Details

WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026.
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact: Jacob Johnson VP, Investor Relations (781) 419-0204 investors@repligen.com

Frequently Asked Questions

When will Repligen report its Q1 2026 financial results?

Repligen will announce its first quarter 2026 financial results on May 5, 2026.

What time is the Repligen conference call?

The conference call is scheduled for 8:00 a.m. ET on May 5, 2026.

How can I access the Repligen conference call?

You can join by calling toll-free at (833) 461-5787 or (585) 542-9983 internationally.

Where can I find the webcast of the conference call?

The webcast will be available in the Investor Relations section of Repligen's website.

What should investors know about forward-looking statements?

Forward-looking statements may involve risks and uncertainties that could impact results.

Last updated: Apr 22, 2026